TBR-065 / Ipsen, Tiburio - LARVOL DELTA

Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors. (PubMed, J Neuroendocrinol) - "Forty-four NF-PitNET primary cultures were treated (72 h, 10 nM) with octreotide (OCT), pasireotide (PAS), OCT + PAS, BIM-53097 (D2R agonist), BIM-53097 + PAS, and BIM-23B065 (SSTR2/SSTR5/D2R preferential ligand) to evaluate cell proliferation inhibition. D2R and SSTR2 can discriminate tumors responsive to BIM-23B065. As concerns the other tested compounds, none of the tumor parameters evaluated demonstrated robust predictive value for NF-PitNET in vitro response."

Journal • Preclinical • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor • SSTR • SSTR2 • SSTR5